ASCO® 2023 Insights: "Biomarker Analysis of 2 Zolbetuximab Phase 3 Studies (SPOTLIGHT & GLOW) - Global Prevalence of CLDN18.2 in Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO® 2023 Insights: "Biomarker Analysis of 2 Zolbetuximab Phase 3 Studies (SPOTLIGHT & GLOW) - Global Prevalence of CLDN18.2 in Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"

By Insights from 2023 ASCO® Annual Meeting FEATURING Kohei Shitara

0 views

June 12, 2023

Comments 0

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini